During the 2007–2008 season, A(H1N1) viruses naturally resistant to oseltamivir due to an H275Y substitution in the neuraminidase emerged and spread in the human population. The neuraminidase of 2007–2008 A(H1N1) viruses has an increased affinity for sialic acids as compared with the N1 of previously circulating viruses.
Methods
Using site-directed mutagenesis analysis and an enzymatic assay on cells transiently expressing the viral neuraminidase, the amino acid changes that could account for the particular enzymatic properties of the neuraminidase of 2007–2008 A(H1N1) viruses were explored. The affinity for the substrate (Km) and the inhibition constants for inhibitors (Ki) were determined for wild-type and mutated neuraminidases. Reverse genetics was used to produce 6:2 reassortant viruses expressing haemagglutinin and neuraminidase derived from A(H1N1) viruses of the 2007–2008 season or from a previously circulating H1N1 virus, in an A/WSN/33 background.
Results
The D344N substitution characteristic of the N1 of 2007–2008 A(H1N1) viruses was identified as a major determinant of its increased affinity for sialic acids. According to the viral plaque phenotype of the 6:2 reas-sortant viruses, the H275Y mutation was deleterious when the surface glycoproteins were derived from the H1N1 virus isolated in 2004, but not when they were derived from A(H1N1) viruses of the 2007–2008 season.
Conclusions
The D344N substitution, by modifying the enzymatic property of the N1, may have favoured the emergence and spread of viruses naturally resistant to oseltamivir.
References
1.
BurchJ., CorbettM., StockC.Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis2009; 9: 537–545.
2.
AokiF.Y., BoivinG., RobertsN.Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther2007; 12: 603–616.
3.
MontoA.S., McKimm-BreschkinJ.L., MackenC.Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother2006; 50: 2395–2402.
4.
SheuT.G., DeydeV.M., Okomo-AdhiamboM.Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother2008; 52: 3284–3292.
DharanN.J., GubarevaL.V., MeyerJ.J.Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA2009; 301: 1034–1041.
7.
HurtA.C., ErnestJ., DengY.M.Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res2009; 83: 90–93.
8.
KramarzP., MonnetD., NicollA., YilmazC., CiancioB.Use of oseltamivir in 12 European countries between 2002 and 2007–lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill2009; 14: 19112.
9.
Rameix-WeltiM.A., EnoufV., CuvelierF., JeanninP., van der WerfS.Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog2008; 4: e1000103.
10.
BazM., AbedY., SimonP., HamelinM.E., BoivinG.Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis2010; 201: 740–745.
11.
Rameix-WeltiM.A., TomoiuA., Dos Santos AfonsoE., van der WerfS., NaffakhN.Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection. J Virol2009; 83: 1320–1331.
12.
Rameix-WeltiM.A., AgouF., BuchyP.Natural variation can significantly alter sensitivity to oseltamivir of Influenza A(H5N1) viruses. Antimicrob Agents Chemother2006; 50: 3809–3815.
13.
WangM.Z., TaiC.Y., MendelD.B.Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother2002; 46: 3809–3816.
14.
BloomJ.D., GongL.I., BaltimoreD.Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science2010; 328: 1272–1275.
15.
GubarevaL.V., KaiserL., MatrosovichM.N., Soo-HooY., HaydenF.G.Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis2001; 183: 523–531.
16.
XuX., ZhuX., DwekR.A., StevensJ., WilsonI.A.Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol2008; 82: 10493–10501.
17.
DominiakP.M., VolkovA., DominiakA.P., JarzembskaK.N., CoppensP.Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibition. Acta Crystallogr D Biol Crystallogr2009; 65: 485–499.
18.
CollinsP.J., HaireL.F., LinY.P.Structural basis for oseltamivir resistance of influenza viruses. Vaccine2009; 27: 6317–6323.
19.
MatrosovichM., MatrosovichT., CarrJ., RobertsN.A., KlenkH.D.Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol2003; 77: 8418–8425.
20.
NelsonM.I., SimonsenL., ViboudC., MillerM.A., HolmesE.C.The origin and global emergence of adamantane resistant A/ H3N2 influenza viruses. Virology2009; 388: 270–278.
21.
World Health Organization.Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec2009; 84: 453–459.
22.
ColmanP.M., VargheseJ.N., LaverW.G.Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature1983; 303: 41–44.
